Prescription Prices and Coupons from GoodRx
Type your drug name (like Atorvastatin, Sildenafil, etc)
Cancel
Advertisement
Afrezza
Afrezza (insulin) is used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There are currently no generic options for any insulin brand, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. Compare insulins.
Prescription Settings
brand
kit
90 cartridges of 4 units
1 kit
Afrezza(brand)
kit
90 cartridges of 4 units
1 kit

Afrezza Latest News

Get the latest updates on this drug from the GoodRx medical team

How Much Does Insulin Cost? – Here’s How 22 Brands Compare

Benita Lee
Benita Lee -

Despite outrage over the high cost of insulin, prices for popular insulin treatments have continued to climb in 2018, according to a GoodRx analysis of drug prices.

Though prices are not climbing as quickly as they did between 2002 and 2013—when the average cost of insulin therapy tripled—the average price of insulin has increased by 64% since January 2014. The most recent price increases are on insulins made by Sanofi-Aventis and Novo Nordisk, which raised prices by as much as 3% in May and July of this year, respectively. See More

Rapid-Acting Versus Long-Acting Insulin: What’s the Difference?

Roni Shye
Roni Shye -

For people who need to take insulin, there are a couple of different typeslong-acting, short-acting, rapid-acting, intermediate-acting, etc. That’s a lot of options!

One question I see most often is the difference between rapid-acting and long-acting insulins. So, let’s get into it.   

What is rapid-acting insulin?

Rapid-acting, or meal-time insulin, is a type of insulin that’s usually taken before, during, or after a meal to lower your blood sugar levels associated with meals. See More

Humalog Junior Insulin Pen Now In Pharmacies

Roni Shye
Roni Shye -

Short-acting insulin is the dose you give yourself to compensate for the amount of food or carbohydrates you eat. Some short-acting insulins include Humalog, Novolog, and Afrezza.

Most of these insulins have been designed for use in adults. However, a new short-acting insulin has been approved for use in children—Humalog Junior KwikPen.

What is Humalog prescribed for?

Humalog is indicated for the treatment of diabetes type 1 and diabetes type 2. See More

This Class of Drugs Causes Almost 100,000 Annual Emergency Visits

Dr. Sharon Orrange
Dr. Sharon Orrange -

Insulin: legal, widely used, and transforms lives. But there are risks—soon you’ll see why we try to spare our type II diabetics from having to start insulin. Using oral medications to their maximum dose and incorporating diet and lifestyle changes is the way to go before resorting to insulin.

Of course, tight blood sugar control is the goal for reducing diabetes related complications (kidney disease, eye disease, neuropathy) but insulin remains one of the most challenging aspects of diabetes management given the risks. See More

FDA Approval: First New Long-Acting Insulins in 10 Years

Roni Shye
Roni Shye -

There have been several new insulin products approved over the past year, including Toujeo, Humalog U-200, Afrezza—and now Tresiba and Ryzodeg.

The other recent insulin approvals are what I like to call spin-off insulin products. For example, Toujeo has the same type of insulin as Lantus (insulin glargine), but is more concentrated. Humalog U-200 is the same exact product as Humalog U-100 (insulin lispro), but once again, more concentrated. See More

Afrezza: The New Inhaled Insulin

Roni Shye
Roni Shye -

Several years ago when I was first starting out as an intern in the retail pharmacy setting, Exubera, an inhaled insulin, was collecting dust on our shelf.

The idea of inhaled insulin sounded great, especially for people who had a phobia of using needles for injection. A few years back there weren’t even as many insulin pen options as there are now, yet Exubera failed and was discontinued.

Despite the failure of Exubera back in October of 2007, a new inhaled insulin, Afrezza, has been FDA approved and is now on the market. See More

Inhaled Insulin: Ten Things You Need to Know

Dr. Sharon Orrange
Dr. Sharon Orrange -

The FDA just approved Afrezza, an inhaled insulin for both Type 1 and Type 2 diabetics. It will be available for prescription very soon, so will there be a run on it? Here are ten points to keep in mind.

  1.  The product will be called Afrezza and was developed by the MannKind Corporation.

  2.  It’s not the first time we’ve heard about inhaled insulin. Exubera, Pfizer’s attempt at inhaled insulin, was never popular because of a possible increase in lung cancer. See More

Copyright ©2018 GoodRx, Inc.
GoodRx is not sponsored by or affiliated with any of the pharmacies identified in its price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders and are used solely to represent the products of these rights holders. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment.
In all states except Tennessee, GoodRx is considered a marketer of prescription discount cards, and is not required to register as a discount card provider. In Tennessee, GoodRx is registered as a Prescription Drug Discount Plan Operator.
LegitScript SealNABP SealBBB Seal